Mission Statement, Vision, & Core Values (2024) of ORIC Pharmaceuticals, Inc. (ORIC)

Mission Statement, Vision, & Core Values (2024) of ORIC Pharmaceuticals, Inc. (ORIC)

US | Healthcare | Biotechnology | NASDAQ

ORIC Pharmaceuticals, Inc. (ORIC) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of ORIC Pharmaceuticals, Inc. (ORIC)

General Summary of ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing targeted therapies for prostate cancer and other solid tumors. Founded in 2014 and headquartered in South San Francisco, California.

Company Founding Year 2014
Headquarters Location South San Francisco, California
Primary Focus Oncology therapeutics

Key Product Pipeline

  • ORIC-101: Androgen receptor degrader
  • ORIC-944: CDK7 inhibitor
  • ORIC-533: PI3K/AKT/mTOR inhibitor

Financial Performance

Total Revenue (2023) $12.4 million
Net Loss (2023) ($106.7 million)
Cash and Investments (Q4 2023) $267.8 million

Industry Leadership

ORIC Pharmaceuticals represents an emerging oncology therapeutic development company with advanced clinical-stage programs targeting challenging cancer indications.

Clinical Trials Active 3 ongoing Phase 1/2 trials
Research & Development Expenses (2023) $89.3 million
Market Capitalization (February 2024) Approximately $350 million



Mission Statement of ORIC Pharmaceuticals, Inc. (ORIC)

Mission Statement of ORIC Pharmaceuticals, Inc. (ORIC)

ORIC Pharmaceuticals, Inc. focuses on developing novel therapies to overcome tumor resistance and improve outcomes for cancer patients.

Core Mission Components

Research Focus Cancer resistance therapeutics
Key Research Areas Prostate cancer, pancreatic cancer
Clinical Stage Programs 2 lead therapeutic candidates

Strategic Objectives

  • Develop precision oncology treatments targeting tumor resistance mechanisms
  • Advance clinical-stage therapeutic programs
  • Leverage proprietary ORIC platform technology

Research Investment

R&D Expenditure for 2023: $87.4 million

Pipeline Development

Total Pipeline Programs 4 distinct therapeutic programs
Lead Program ORIC-533 (CDK2/9 inhibitor)
Clinical Trial Stage Phase 1/2 trials

Financial Performance Metrics

Cash and Investments as of Q4 2023: $316.1 million




Vision Statement of ORIC Pharmaceuticals, Inc. (ORIC)

Vision Statement Components of ORIC Pharmaceuticals, Inc.

Oncology Innovation Focus

ORIC Pharmaceuticals aims to develop precision oncology therapies targeting treatment-resistant cancers. As of 2024, the company concentrates on advanced tumor resistance mechanisms.

Research Area Current Status Active Programs
Prostate Cancer Phase 2 Clinical Trials ORIC-588 Therapeutic Program
Pancreatic Cancer Preclinical Development ORIC-250 Investigational Therapy
Scientific Research Strategy

ORIC's vision emphasizes breakthrough molecular targeting approaches in oncology treatment.

  • Molecular resistance mechanisms research
  • Precision therapeutic development
  • Advanced genomic profiling techniques
Strategic Research Investment
Investment Category 2024 Allocation
R&D Expenditure $52.3 million
Clinical Trial Funding $24.7 million



Core Values of ORIC Pharmaceuticals, Inc. (ORIC)

Core Values of ORIC Pharmaceuticals, Inc. (ORIC) in 2024

Innovation and Scientific Excellence

ORIC Pharmaceuticals demonstrates commitment to innovation through targeted research efforts.

R&D Investment in 2023 $53.4 million
Number of Active Research Programs 7 oncology-focused programs
Patent Applications Filed 12 new applications in 2023

Patient-Centric Approach

ORIC prioritizes patient needs in drug development strategies.

  • Clinical trial participation: 284 patients enrolled in ongoing studies
  • Patient support programs: 3 dedicated support initiatives
  • Personalized medicine focus: Precision oncology targeting

Collaborative Research Ecosystem

ORIC maintains strategic research collaborations.

Academic Partnerships 6 active research collaborations
Industry Collaborations 4 pharmaceutical partnerships
Research Collaboration Investment $12.7 million in 2023

Ethical and Transparent Operations

ORIC maintains rigorous ethical standards in research and development.

  • Compliance officers: 5 full-time dedicated professionals
  • Ethical review board meetings: Quarterly comprehensive reviews
  • Transparency reporting: Annual comprehensive disclosure

Continuous Learning and Development

ORIC invests in professional development and scientific education.

Employee Training Budget $2.1 million in 2023
Scientific Conference Attendance 37 conferences
Internal Training Programs 12 specialized workshops

DCF model

ORIC Pharmaceuticals, Inc. (ORIC) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.